ImmunityBio partners with Accord Healthcare, Uniphar to expand ANKTIVA access in Europe
IBRX•ImmunityBio is collaborating with Accord Healthcare and Uniphar to expand European access to ANKTIVA. The first patients received ANKTIVA with BCG in Germany and Austria, following European Commission conditional marketing authorization in February 2026.
1. European access partnership
ImmunityBio is collaborating with Accord Healthcare and Uniphar to expand European access to ANKTIVA, its bladder cancer therapy. Accord will provide commercial expertise and market access support, while Uniphar will handle supply chain and distribution services.
2. First patients treated
The first European patients received ANKTIVA with BCG in Germany and Austria for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. The European Commission’s conditional marketing authorization, granted in February 2026, covers all 27 EU member states, Iceland, Norway and Liechtenstein.
